Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, PK and Efficacy of Retapamulin Ointment, 1% Applied Twice Daily for 3 or 5 Days to the Anterior Nares of Healthy Adult Subjects Nasally Colonized With Staphylococcus Aureus.

Trial Profile

Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, PK and Efficacy of Retapamulin Ointment, 1% Applied Twice Daily for 3 or 5 Days to the Anterior Nares of Healthy Adult Subjects Nasally Colonized With Staphylococcus Aureus.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Jun 2015

At a glance

  • Drugs Retapamulin (Primary)
  • Indications Staphylococcal infections
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 03 Dec 2008 Results were published at ICAAC 2008.
    • 12 Oct 2008 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
    • 20 Feb 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top